Authors: Slah Ouerhani Karim Bougatef Ismail Soltani Amel Ben Ammar Elgaaied Salem Abbes Samia Menif
Publish Date: 2013/05/03
Volume: 40, Issue: 6, Pages: 4109-4114
Abstract
Mutations in the KRAS gene have been shown to play a key role in the pathogenesis of a variety of human tumours However the mutational spectrum of KRAS gene differs by organ site In this study we have analysed the mutational spectrum of KRAS exon 1 in bladder tumours colorectal cancer CRC and chronic myeloid leukemia CML A total of 366 patients were included in the present study 234 bladder tumours 48 CRC and 84 CML The KRAS mutations are absent in BCR/ABL1 positive CML This result suggests that BCR/ABL1 fusion gene and KRAS mutations were mutually exclusive The frequency of KRAS mutations in bladder cancer was estimated at 427 All of mutations were found in codon 12 and 90 of them were detected in advanced bladder tumours However the correlation between KRAS mutations and tumour stage and grade does not report a statistical significant association The KRAS mutations occur in 3541 of patients with CRC The most frequent mutations were G12C G12D and G13D These mutations were significantly correlated with histological differentiation of CRC p = 0024 Although the high frequency of KRAS in CRC in comparison to bladder cancer these two cancers appear to have the same mutational spectrum p 005
Keywords: